The methacholine bronchial provocation test is a useful tool for evaluating asthma in patients with normal or near normal baseline lung function. However, the sensitivity of this test is 82∼92% at most. The purpose of this study is to evaluate the clinical usefulness of FEF 25-75% in identification of airway hyperresponsiveness in patients with suspected asthmatic symptoms. Methods: One hundred twenty-five patients who experienced cough and wheezing within one week prior to their visiting the clinic were enrolled. Results: Sixty-four subjects showed no significant reduction of FEV1 or FEF25-75% on the methacholine bronchial provocation test (Group I). In 24 patients, FEF25-75% fell more than 20% from baseline without a 20% fall of FEV1 during methacholine challenge (Group II). All patients who had more than 20% fall of FEV 1 (n=37) also showed more than 20% of reduction in FEF25-75% (Group III). Baseline FEV1/FVC (%) and FEF25-75% (L) were higher in group II than group III (81.51±1.56% vs. 75.02±1.60%, p＜0.001, 3.25±0.21 L vs. 2.45±0.21 L, p=0.013, respectively). Group II had greater reductions of both FEV 1 and FEF 25-75% than group I at 25 mg/mL of methacholine (p＜0.001). The provocative concentration of methacholine causing a 20% fall in FEF25-75% in group II was about three-fold higher than that in group III. Conclusion: A 20% fall of FEF 25-75% by methacholine provocation can be more sensitive indicator for detecting a milder form of airway hyperresponsiveness than FEV1 criteria.
Introduction
Asthma is a chronic airway inflammatory disease with a growing global prevalence. Wheezing, breathlessness, and cough are the major symptoms of asthma, but patients complain of variety of combinations of these symptoms. A combination of wheezing and dyspnea has the greatest positive predictive value for the diagnosis of asthma 1 . The bronchial provocation test is an important diagnostic tool to identify airway hyperresponsiveness in asthma 2 . Several textbooks indicate that negative result in the methacholine provocation test rules out asthma as a cause of chronic cough because the bronchial provocation test has very high sensitivity and negative predictive value 3 . However, in real practice, we frequently fail to prove the presence of airway hyperresponsiveness by the methacholine provocation test in patients with typical asthmatic symptoms. The positive rates of methacholine provocation test were 79.5% in physician-diagnosed asthma and only 37.7% in chronic cough with wheezing in Korea 4, 5 . Traditionally, the methacholine provocation test uses the 'Forced Expiratory Volume in 1 second (FEV1)' to identify bronchial hyperresponsiveness. The 'Forced Expira-
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tory Flow 25-75% (FEF 25-75% )' is a more sensitive indicator for the obstruction of small airways than FEV1, but has lower reproducibility than FEV 1 . However, the insufficient sensitivity of the methacholine provocation test based on FEV 1 necessitates the development of a more sensitive indicator. Thus we evaluated the role of a provocative concentration of methacholine causing a 20% fall in FEF25-75% (FEF25-75%-PC20) compared with PC20 in FEV 1 (FEV 1 -PC20) to identify airway hyperresponsiveness in patients with suspected asthmatic symptoms.
Materials and Methods

Patients
Patients with cough and wheezing were recruited for this retrospective study. Eligible patients' records were acquired from the chronic cough database of Hallym University Sacred Heart Hospital between October, 2004 and July, 2007. Inclusion criteria were the followings: age over 15, current or a recent wheezing experience within one week prior to visiting the cough clinic, and a tolerable physical condition for the methacholine provocation test. Suspicious COPD, structural lung disease, tuberculosis, heart failure, and pulmonary edema were excluded. Smoking status was not considered in the selection criteria. After careful medical history taking and physical exams, chest and paranasal sinus view x-ray, differential cell count in induced sputum, and the methacholine bronchial provocation test were performed to identify the cause of cough and wheezing. The study design was approved by the institutional ethics committee.
Methacholine bronchial provocation test
The methacholine bronchial provocation test was performed as described by Chai et al 6 . After the baseline pulmonary function, methacholine aerosol at 0.625, 1.25, 2.5, 12.5, and 25 mg/mL was delivered with a compressor (Pulmo-Aide 5650D, DeVibliss Health Care, Somerset, PA, USA) and an aerosolizer (DeVibliss 646, DeVibliss Health Care). The patients inhaled the aerosol quantified by KoKo-MSM analog micro-dosimeter (nSpire Health, Inc. Longmont, CO, USA) slowly for five seconds and then held their breath for five seconds. The patients repeated this procedure 5 times, and then FEV 1 was measured repeatedly after 30 and 90 seconds. The highest FEV 1 was included in the analysis 7 . The methacholine challenge test was stopped when FEV1 had fallen more than 20% from baseline or the final methacholine concentration of 25 mg/mL was applied. PC20 was calculated by linear interpolation regarding FEV 1 fall (FEV 1 -PC20) and FEF 25-75% fall (FEF 25-75% -PC20). Patients were classified as positive responders when the PC20 was lower than 25 mg/mL. The patients were grouped according to methacholine provocation test: Group I, patients with both FEF 25-75% -PC20 and FEV 1 -PC20 ＞25 mg/mL; Group II, patients with FEF 25-75% -PC20 ≤25 mg/mL and FEV 1 -PC20 ＞25 mg/ mL; Group III, both FEF 25-75% -PC20 and FEV 1 -PC20 ≤25 mg/mL.
Differential cell count in induced sputum
After measuring the baseline FEV 1 , the patients gargled with water and wiped their mouths with dry gauze. Sputum was induced with 15 mL of 4.5% hypertonic saline aerosol inhalation for five minutes. Afterwards the patients rinsed their mouth with water, and then expectorate sputum in a 50 mL Falcon tube. This procedure was repeated three to four times. The collected sputum was immediately treated with an equal volume of 0.15% (0.01 M) dithiothreitol dissolved in PBS and rocked for 30 minutes. Then it was filtered through a 100 μm mesh strainer and centrifuged at 2,000 rpm for five minutes at 4 o C. The cell pellet was resuspended with 5 mL of PBS for differential cell count after careful removal of the supernatant. Cytospins were Wright-stained and differential cell counting of macrophages, neutrophils, lymphocytes, and eosinophils was done for more than 300 non-squamous cells. According to eosinophil percentages, patients were divided into two groups: increased eosinophil count (sputum eosinophilia) ≥3%, or normal eosinophil count ＜3%. 
Data analysis
Independent samples t-tests were used to compare continuous variables from two groups. One-way ANOVA was used to compare three groups. Categorical variables were analyzed by chi-square test. Trends were analyzed by chi-square for linear trend. p-value ＜0.05 was considered significant.
Results
Characteristics of the patients
A total of 125 patients were enrolled for the analysis. Fifty-three patients were male and 72 were female. Sixty-four patients were classified in group I, 24 patients in group II, and 37 patients in group III according to the methacholine provocation test ( Table 1 ). The mean age was 43.4±1.4 years and there was no difference among the groups. Group II was younger than the others, but not significantly. Eight (6.4%) of them had a medical history of bronchial asthma, 34 (27.2%) had allergic rhinitis, and 11 (8.8%) had previous atopic dermatitis. The duration of cough was 12.9±5.1 weeks in group I, 7.9±3.4 weeks in group II, and 15.0±7.9 weeks in group III, but the differences were not statistically significant. The treatment duration in the outpatient clinic was 8.8±2.0 weeks in group I, 14.4±5.8 weeks in group II, and 37.1±7.2 weeks in group III (p＜0.001).
Pulmonary function tests
Group III showed the lowest mean values in all the parameters related with airway obstruction, such as FEV 1 , FEF 25-75% , FEV 1 /FVC, and FEF 25-75% /FVC ( Table 2) . Group II showed a greater reduction of FEV 1 and FEF 25-75% at the highest methacholine concentration of 25 mg/mL compared with group I. The FEV 1 changes for group I and group II at 25 mg/mL were 6.6±0.6% vs. 12.7±0.7%, respectively (p＜0.001). The FEF 25-75% falls of group I and group II at 25 mg/mL were 1.4±1.8% vs. 28.4±1.7%, respectively (p＜0.001) ( Figure 1A ). The FEF 25-75% -PC20 of group II was about three-fold higher than that of group III (20.5±1.5 mg/mL vs. 7.4±1.0 mg/mL, respectively, p＜0.001) ( Figure 1B ). These findings suggest that the bronchial hyperresponsiveness increased in group I, II, and III.
Eosinophil count in induced sputum
Sputum eosinophilia was present in 39 (31.2%) patients. The proportion of patients with sputum eosinophilia significantly increased with a rank order for group (Figure 2A ). Mean PC20 based on either FEV 1 or FEF 25-75% were significantly lower in patients with sputum eosinophilia. The FEV 1 -PC20 in group III patients with or without sputum eosinophilia was insignificant (9.9±1.8 mg/mL vs. 13.4±2.0 mg/mL respectively, p=0.203), but FEF25-75%-PC20 in group II and III patients with sputum eosinophilia was significantly lower than in patients without sputum eosinophilia (9.3±1.7 mg/mL vs. 14.4±1.6 mg/mL respectively, p=0.032) ( Figure 2B ). Twenty-two patients with sputum eosinophilia and 33 patients without sputum eosinophilia underwent bronchodilator response test. The positive rate of bronchodilator response (≥ 12% and ≥200 mL from baseline in FEV 1 ) was higher in patients with sputum eosinophilia than in the patients without sputum eosinophilia (22.72% vs. 6.06%, p=0.027).
Discussion
Bronchial asthma is characterized by variable airway obstruction due to constriction and edema of bronchus; therefore, a pulmonary function test with bronchodilators is used as an objective tool to prove the airway reversibility in symptomatic asthmatics. If lung function is normal or near normal at rest, non-specific bronchial The difference of FEV1-PC20 was insignificant between the patients with sputum eosinophilia and without sputum eosinophilia (p=0.203), but FEF 25-75% -PC20 was significantly lower in the patients with sputum eosinophilia than in the patients without sputum eosinophilia (*p=0.032, t-test). The results are expressed as mean±SEM.
provocation test can be done to confirm the presence of airway hyperresponsiveness 1 . Methacholine is a chemically stable acetylcholine-like substance that constricts the bronchial smooth muscle directly by cholinergic stimulation. Although methacholine is one of the most widely used non-specific bronchial stimulants, there is no unanimously adopted method for the methacholine bronchial provocation test. On inhaling methacholine, two different methods are frequently used, the 5-breath technique and tidal volume method 7 . The cutoff value of PC20 for positive response varies from 8 to 16 mg/mL. Despite the reported good test sensitivity, false negative can also present 2 . For example, extremely trained athletes, patients on bronchodilators or anticholinergic drugs, and patients without current symptoms or exposure allergen can show false negatives. Full inspiration up to total lung capacity (TLC) has a protective effect on bronchial constriction; therefore TLC inhalation with the 5-breath technique can produce false negatives in patients with weak airway hyperresponsiveness 8, 9 . Coffee, tea, cola, and chocolate taken on the test day can also affect the test results. Perpina et al 10 reported that the cutoff value of 25 mg/mL for PC20 had a sensitivity of 87% and raising it to 70 mg/mL gave 100% sensitivity. Based on their study, the conventional methacholine challenge test could miss many asthma patients. Asthma is a small airway disease and FEV 1 is commonly used as a marker for bronchial narrowing in asthmatics. Although FEF25-75% also reflects small airway obstruction, it is not commonly used in real practice because it is less reproducible than FEV 1 . However, in healthy soldiers, FEF 25-75% could be an early marker for small airway disease when FEV 1 or FEV 1 /FVC were normal 11 , and FEF 25-75% can be more sensitive in the methacholine bronchial provocation test 12 . One study in children with asthma showed that FEF25-75% was the most sensitive marker for detecting reduction in lung functions including FEV 1 and FEV 1 /FVC 13 . In the methacholine provocation test in children, a 25% decrease of FEF 25-75% revealed a close correlation with a 20% decrease of FEV1 14 . In this study, only one third of the patients were classified as having airway hyperresponsiveness by FEV 1 -PC20 criteria despite the history of current or recent wheezing. With such low positive rate of FEV 1 -PC20 in potential asthma patients, we needed more sensitive tool to detect mild airway hyperresponsiveness. Using a 20% fall in FEV25-75%, 20% more patients could be diagnosed with asthma. These patients were younger and had better basal lung function than the typical asthma group defined by FEV1-PC20 criteria. In addition, the average time on treatment was significantly shorter than typical asthma patients. Thus, patients with a 20% fall of FEF 25-75% had a milder, earlier form of asthma.
Sputum eosinophilia reflects eosinophilic inflammation in the central airway and is frequently observed in asthma patients [15] [16] [17] . In this study, the percentage of patients with sputum eosinophilia showed a linear trend in the order of group I, II, and III. Although both group I and group II were classified as methacholine-negative by FEV 1 -PC20 criteria, group II had higher proportion of sputum eosinophil and reduction of lung function at 25 mg/mL of methacholine. Patients with sputum eosinophilia in group I and II could be diagnosed with eosinophilic bronchitis or atopic cough, but would have different clinical courses. In the literature, approximately 10% of eosinophilic bronchitis evolves to asthma 18, 19 . We speculate that some patients in group II have an early, milder form of asthma and would eventually progress to typical asthma.
